1. Home
  2. AGD vs ACIU Comparison

AGD vs ACIU Comparison

Compare AGD & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Global Dynamic Dividend Fund of Beneficial Interest

AGD

abrdn Global Dynamic Dividend Fund of Beneficial Interest

SELL

Current Price

$11.29

Market Cap

300.7M

Sector

Finance

ML Signal

SELL

Logo AC Immune SA

ACIU

AC Immune SA

SELL

Current Price

$2.41

Market Cap

247.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AGD
ACIU
Founded
N/A
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
300.7M
247.6M
IPO Year
2006
2015

Fundamental Metrics

Financial Performance
Metric
AGD
ACIU
Price
$11.29
$2.41
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $8.57
AVG Volume (30 Days)
84.7K
★ 190.0K
Earning Date
01-01-0001
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$422.39
Revenue Next Year
N/A
$377.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.41
$2.10
52 Week High
$12.89
$4.00

Technical Indicators

Market Signals
Indicator
AGD
ACIU
Relative Strength Index (RSI) 39.15 38.49
Support Level $10.41 $2.13
Resistance Level $12.27 $2.96
Average True Range (ATR) 0.19 0.15
MACD -0.02 -0.03
Stochastic Oscillator 28.22 5.10

Price Performance

Historical Comparison
AGD
ACIU

About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest

Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: